News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis

Posted on

SAN ANTONIO–(BUSINESS WIRE)–Santalis Pharmaceuticals today announced positive results from its single-center, open-label, efficacy and tolerability proof-of-concept study using a proprietary 10% East Indian Sandalwood Oil (EISO) serum formulation for the treatment of mildto-moderate plaque psoriasis. The results of the study showed the EISO serum formulation to be safe, well tolerated, and efficacious for patients 18 to 65 years of age […]Read More Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis

Posted on

Santalis Pharmaceuticals today announced it has enrolled its first patient into a single-center, open label, efficacy and tolerability proof of concept study using a unique 10% East Indian Sandalwood Oil (EISO) serum formulation for the treatment of mild to moderate plaque psoriasis. Patients will be at least 18 years of age with a maximum of 10% treatable body surface area […]Read More Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis

Santalis Announces Positive Results for Pediatric Atopic Dermatitis Treatment

Posted on

Santalis Pharmaceuticals announced in a press release positive preliminary results from an expanded study of its Santalia AD product regimen for treating pediatric atopic dermatitis. The over-the-counter products contain East Indian sandalwood oil and colloidal oatmeal, according to the release. The study was conducted on 25 patients, aged 3 months to 12 years,¬†with mild, moderate or severe atopic dermatitis with […]Read More Santalis Announces Positive Results for Pediatric Atopic Dermatitis Treatment